---
title: "JonesTrading Remains a Buy on Protara Therapeutics (TARA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281802899.md"
description: "JonesTrading analyst Soumit Roy has maintained a Buy rating on Protara Therapeutics (TARA) with a price target of $25.00. Roy, who focuses on the Healthcare sector, has an average return of -7.2% and a 32.22% success rate on his stock recommendations. Additionally, Protara received a Buy rating from Piper Sandler's Kelsey Goodwin, while TipRanks reiterated a Hold rating on March 30."
datetime: "2026-04-06T20:38:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281802899.md)
  - [en](https://longbridge.com/en/news/281802899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281802899.md)
generator: "portal-rs"
---

# JonesTrading Remains a Buy on Protara Therapeutics (TARA)

JonesTrading analyst Soumit Roy maintained a Buy rating on Protara Therapeutics today and set a price target of $25.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -7.2% and a 32.22% success rate on recommended stocks. 

In addition to JonesTrading, Protara Therapeutics also received a Buy from Piper Sandler’s Kelsey Goodwin in a report issued on March 26. However, on March 30, TipRanks – Google reiterated a Hold rating on Protara Therapeutics (NASDAQ: TARA).

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26](https://longbridge.com/en/news/295589045.md)
- [Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen](https://longbridge.com/en/news/295992564.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Protara Therapeutics Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295534784.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**